Arcus Biosciences (RCUS) Non-Current Deffered Revenue (2017 - 2026)

Arcus Biosciences' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $45.0 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 79.45% year-over-year to $45.0 million in Q1 2026; TTM through Mar 2026 was $45.0 million, a 79.45% decrease from a year earlier, with the FY2025 full-year figure at $43.0 million, down 81.62% from the prior year.
• Non-Current Deffered Revenue advanced to $45.0 million in Q1 2026 per RCUS's latest filing, from $43.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $456.9 million in Q1 2022 and bottomed at $43.0 million in Q4 2025.
• The 5-year median for Non-Current Deffered Revenue is $289.0 million (2024), against an average of $253.9 million.
• Across the five-year window, Non-Current Deffered Revenue jumped 313.19% in 2022 and tumbled 81.66% in 2025, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $355.0 million in 2022, then declined by 13.52% to $307.0 million in 2023, then declined by 23.78% to $234.0 million in 2024, then slumped by 81.62% to $43.0 million in 2025, then increased by 4.65% to $45.0 million in 2026.
• Per Business Quant, the three latest RCUS Non-Current Deffered Revenue figures stand at $45.0 million (Q1 2026), $43.0 million (Q4 2025), and $53.0 million (Q3 2025).